Moderna, Inc. (NASDAQ:MRNA) Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC decreased its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 83.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 70,253 shares of the company's stock after selling 359,045 shares during the quarter. ProShare Advisors LLC's holdings in Moderna were worth $2,921,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Allworth Financial LP raised its position in Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company's stock valued at $73,000 after purchasing an additional 281 shares during the last quarter. Howard Capital Management Inc. raised its position in Moderna by 3.1% during the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after buying an additional 297 shares during the last quarter. Itau Unibanco Holding S.A. raised its position in Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after buying an additional 343 shares during the last quarter. Commonwealth Equity Services LLC raised its position in Moderna by 0.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock worth $3,099,000 after buying an additional 345 shares during the last quarter. Finally, Larson Financial Group LLC raised its position in Moderna by 39.1% during the 4th quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock worth $53,000 after buying an additional 356 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Analyst Ratings Changes

MRNA has been the subject of a number of analyst reports. The Goldman Sachs Group downgraded shares of Moderna from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Citigroup initiated coverage on shares of Moderna in a research report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price objective for the company. Evercore ISI cut their price objective on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Barclays cut their price objective on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research report on Friday, May 2nd. Finally, William Blair restated a "market perform" rating on shares of Moderna in a research report on Thursday, April 17th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $53.58.

Moderna Stock Performance

NASDAQ MRNA traded down $0.46 during trading hours on Friday, reaching $26.26. The company's stock had a trading volume of 8,237,982 shares, compared to its average volume of 7,997,199. The stock has a market cap of $10.16 billion, a PE ratio of -2.83 and a beta of 1.99. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47. The company's 50-day moving average is $27.23 and its two-hundred day moving average is $34.81.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. The firm had revenue of $108.00 million for the quarter, compared to analysts' expectations of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm's revenue was down 35.3% on a year-over-year basis. During the same period in the prior year, the company earned ($3.07) EPS. Equities analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.